Cellectar Biosciences Inc (NASDAQ: CLRB)’s stock price has increased by 106.66 compared to its previous closing price of 0.28. However, the company has seen a 133.40% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-04 that Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
Additionally, the 36-month beta value for CLRB is 0.52. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLRB is 45.31M and currently, short sellers hold a 5.27% ratio of that float. The average trading volume of CLRB on June 04, 2025 was 972.43K shares.
CLRB’s Market Performance
CLRB stock saw an increase of 133.40% in the past week, with a monthly gain of 115.60% and a quarterly increase of 88.90%. The volatility ratio for the week is 4.71%, and the volatility levels for the last 30 days are 4.95% for Cellectar Biosciences Inc (CLRB). The simple moving average for the last 20 days is 112.98% for CLRB stock, with a simple moving average of -40.89% for the last 200 days.
Analysts’ Opinion of CLRB
Many brokerage firms have already submitted their reports for CLRB stocks, with Ladenburg Thalmann repeating the rating for CLRB by listing it as a “Buy.” The predicted price for CLRB in the upcoming period, according to Ladenburg Thalmann is $13 based on the research report published on December 05, 2024 of the previous year 2024.
ROTH Capital gave a rating of “Buy” to CLRB, setting the target price at $10 in the report published on January 21st of the previous year.
CLRB Trading at 102.52% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.23% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLRB starting from Longcor Jarrod, who purchase 30,000 shares at the price of $0.28 back on Jan 10 ’25. After this action, Longcor Jarrod now owns 83,141 shares of Cellectar Biosciences Inc, valued at $8,400 using the latest closing price.
Stock Fundamentals for CLRB
The total capital return value is set at -4.61. Equity return is now at value -208.72, with -83.27 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -100.31.
Currently, EBITDA for the company is -44.22 million with net debt to EBITDA at 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.47.
Conclusion
In conclusion, Cellectar Biosciences Inc (CLRB) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
